Trial Profile
Neoadjuvant Weekly Nab-Paclitaxel (Abraxane) Plus Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently To Chemotherapy For Palpable And Operable Triple Negative Invasive Breast Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Adenocarcinoma; Early breast cancer; Triple negative breast cancer
- Focus Biomarker; Therapeutic Use
- 31 May 2013 Data presented at the 2013 American Society for Clinical Oncology (ASCO) Meeting, according to a West Clinic media release.
- 03 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Feb 2012 Planned end date changed from 1 Oct 2011 to 1 Oct 2013 as reported by ClinicalTrials.gov.